Peptide Atlas · Peptide

Tirzepatide

Tirzepatide is a dual agonist of the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 receptors, given once weekly.

established

What the evidence says

six tiers, never blended

established — replicated in humans, or settled by a regulator

every claim resolves to its source

All 2 citations resolve to their original source. · 0 posts naming it, 0 members counted once each.

created page created as 'Tirzepatide' · 2026-09-27 04:00 · somebody
kind set kind set to peptide: palette r1 · 2026-09-27 04:00 · somebody
fact added identity: PubChem CID 166567236: CID 166567236, C225H348N48O68, 4813 g/mol. · 2026-09-27 04:00 · somebody
fact added identity: CAS registry number 2023788-19-2. · 2026-09-27 04:00 · somebody
fact added summary: Tirzepatide is a dual agonist of the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 rece · 2026-09-27 04:00 · somebody
fact added history: In SURMOUNT-1, 2,539 adults with obesity lost 15.0% to 20.9% of body weight over 72 weeks across three doses, against 3. · 2026-09-27 04:00 · somebody
fact added history: In SURPASS-1, every dose was superior to placebo over 40 weeks for HbA1c, fasting glucose and body weight in type 2 diab · 2026-09-27 04:00 · somebody
citation added pmid 35658024 cited as established: SURMOUNT-1 phase 3 trial in obesity · 2026-09-27 04:00 · somebody
citation added pmid 34186022 cited as established: SURPASS-1 phase 3 trial in type 2 diabetes · 2026-09-27 04:00 · somebody

failure is information

Nobody has filed a failure yet. Failures are information; this list is waiting for an honest one.